Neuroloop: A Novel Vagus Nerve Stimulation Device for Hypertension Treatment Developed by B. Braun

Hypertension can be diagnosed if blood pressure exceeds 140/90 mmHg on three separate occasions without the use of antihypertensive medications.Hypertension is a cardiovascular syndrome characterized by diverse etiologies, insidious onset, and severe hazards, necessitating long-term comprehensive treatment.

The "2025 Global Hypertension Report" released by the World Health Organization in September 2025 shows that the number of people with hypertension worldwide reached 1.4 billion in 2024, but only about one-fifth of patients effectively controlled their condition through medication or lifestyle interventions. In 2024, approximately 29% of Chinese adults aged 30 to 79 (about 270 million people) suffered from hypertension. Among them, only 57% were aware of their condition, 43% received treatment, and only 18% achieved effective control.

Currently, the most effective treatment for hypertension remains the use of antihypertensive medications, even though renal denervation (RDN) technology is available (currently, RDN technology is only applicable toHypertensive patients requiring dose reduction in the adjunctive treatment of refractory hypertension and drug-intolerant hypertension）。

Therefore, whether using antihypertensive medications or renal denervation (RDN), these interventions can only delay the progression of hypertension but cannot alter its symptoms. Hence, innovative technologies remain essential for the treatment of hypertension.

Therefore, B. Braun's subsidiary in 2016Aesculap AG collaborates with the University of Freiburg (and Freiburg University Hospital) to establish an innovative medical device company---neuroloop GmbH。The company provides a global hypertension treatment technology—by stimulatingVagus Nerve Achieves Blood Pressure Reduction---neuroloop 。

neuroloop

NeuroloopsComposed of a unique, patented ultra-thin multi-channel cuff electrode that wraps around the vagus nerve. The electrode is connected to a pulse generator implanted in the chest, which features wireless charging and programming capabilities.NeuroloopsSelective vagus nerve stimulation sets a new standard for the treatment of chronic diseases associated with autonomic vital functions.

Therapeutic Principle

The principle of using vagus nerve stimulation (VNS) to treat hypertension involves selectively stimulating the baroreceptor fibers in the left vagus nerve, while avoiding concurrent stimulation of other vagal segments. This selectivity can be achieved using a novel multi-contact cuff electrode (MCE) made of polyimide and containing more than ten contacts.

Preclinical studies have demonstrated that blood pressure in rats can be reduced to 40% of baseline without causing significant bradycardia. Interference with commonly used antihypertensive drugs appears to be minimal. This method of activating the baroreflex seems to maintain lowered blood pressure even in the absence of continuous stimulation and is synchronized with the electrocardiogram (ECG).

neuroloop GmbH

neuroloop GmbHis an innovative medical device company,Committed to advancing personalized therapy through the application of cutting-edge neuromodulation technologies. We strive to provide non-pharmacological alternatives for patients with chronic conditions, in collaboration with our partners.